Water intake keeps type 2 diabetes away? Focus on copeptin by Muscogiuri, Giovanna et al.
Endocrine (2018) 62:292–298
https://doi.org/10.1007/s12020-018-1680-7
MINI REVIEW
Water intake keeps type 2 diabetes away? Focus on copeptin
Giovanna Muscogiuri1 ● Luigi Barrea1 ● Giuseppe Annunziata1 ● Martina Vecchiarini2 ● Francesco Orio3 ●
Carolina Di Somma4 ● Annamaria Colao1 ● Silvia Savastano1
Received: 23 January 2018 / Accepted: 9 July 2018 / Published online: 19 July 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018
Abstract
Introduction In both diabetic subjects and animal models high levels of vasopressin (AVP) have beendetected. The rela-
tionship between AVP and glucose metabolism is mediated through several direct andindirect effects and most of them are
still unknown.
Methods We have reviewed 100 manuscripts retrieved from Cochrane Library, Embase and Pubmeddatabases in order to
highlight a possible relationship between copeptin and type 2 diabetes and to provideinsights on the molecular mechanism
that could explain this association.
Results and conclusions AVP potentiates CRH action at pituitary level resulting in an increased ACTH secretion and in turn
in an increased cortisol secretion that escapes the negative feedback loop. Further, AVP regulates insulin and glucagon
secretion through V1b receptor and promotes hepatic glycogenolysis and gluconeogenesis through V1a receptor. In addition
to worsen glucose metabolism, AVP has been reported to have a role in the pathogenesis of diabetic complications such as
cardiovascular diseases, kidney and ocular complications. Due to the very low concentration of AVP in the blood, the small
size and poor stability, the assay of AVP is very difﬁcult to perform. Thus, copeptin, the stable C-terminal portion of the
prepro-vasopressin peptide has been identiﬁed as an easier assay to be measured and that mirrors AVP activity. Although
there are promising evidence that copeptin could be involved in the pathogenesis of type 2 diabetes, further studies need to
demonstrate the importance of copeptin as clinical marker to predict glucose metabolism derangements.
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Abbreviation
AVP Arginine vasopressin
PREVEN-
D
Prevention of renal and vascular end-stage
disease
HIF-1 Hypoxia-inducible factor-1
CAD Coronary artery disease
HF Heart failure
SGK1 Serum and glucocorticoid inducible kinase 1
SGLT1 Sodium glucose transporter 1
Introduction
High water intake has been reported to have a beneﬁcial
effect in the management of diabetes [1, 2]. However,
recent evidence showed that the mechanisms are much more
complex and that hide a hormonal milieu. The main actor
has been identiﬁed in arginine vasopressin (AVP), also
termed antidiuretic hormone. AVP is produced in hypo-
thalamus and released by posterior pituitary (neurohypo-
physis) in a condition of high plasma osmolality, low
plasma volume and low blood pressure [3]. Besides pre-
serving the ﬂuid homeostasis, AVP has a role in stimulating
hepatic gluconeogenesis and glycogenolysis and the secre-
tion of glucagon and insulin dependent on the extracellular
glucose concentration [4–6]. Indeed it has been reported
that mice knock out for V1a and/or V1b vasopressin
receptors could have metabolic disorders related to glucose
metabolism ranging from insulin hypersensitivity and
increased glucose tolerance till insulin resistance, obesity,
and impaired glucose tolerance [7–9]. Increased AVP levels
have been detected in people with diabetes [10] and these
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data were conﬁrmed in animal studies in which spontaneous
or streptozotocin-induced diabetes has been associated to an
increase of AVP [11, 12]. However, the main limit of the
use of AVP as marker to predict impairment of glucose
metabolism is represented by its very low concentration in
the blood, the small size and poor stability that makes dif-
ﬁcult the assay. This issue prompted the researchers to ﬁnd
an alternative marker that could be representative of AVP
levels. Copeptin, the stable C-terminal portion of the
prepro-vasopressin peptide has been identiﬁed as an easier
assay that was shown to tightly correlated with AVP levels
and mostly with hydration status (a mirror of AVP activity)
[13, 14]. Interestingly copeptin has been found to be a
marker associated to the risk of developing insulin resis-
tance, metabolic syndrome, and type 2 diabetes [15, 16].
This could be due to AVP that could stimulate the V1b
receptors that are located in the anterior pituitary and that
contribute to the stimulation of ACTH secretion [17]. As
well known, an overstimulation of ACTH secretion results
in an increased secretion of cortisol that at high levels has a
detrimental effect on glucose metabolism. Besides this
indirect mechanism, it has been found a direct action of
AVP on liver through V1b receptor having an effect on
hepatic glycogenolysis and gluconeogenesis [5, 6]. Thus,
the aim of this manuscript is to provide an overview of
observational studies that have investigated the association
of copeptin with type 2 diabetes and to review the molecular
evidence that could explain this link.
Search strategy
A comprehensive search of Cochrane Library, Embase and
Pubmed was conducted using using at least one of the
following terms: obesity and/or type 2 diabetes and/or water
and/or glucagon and/or copeptin and/or vasopressin.
Reference lists of included studies and review papers were
screened for relevance and hand searching of relevant
reports done. Articles in the English language were the only
ones eligible for inclusion in the manuscript.
Epidemiological evidence
The association of copeptin with the risk of developing type
2 diabetes has been investigated in the Malmo Diet and
Cancer Study showing that there was an independent
association between copeptin with fasting insulin and blood
glucose [18]. These data were not conﬁrmed in the FIN-
RISK97 Study that conversely reported the lack of an
association of copeptin with diabetes after adjustment for
metabolic risk factors [19]. However, the Prevention of
Renal and Vascular End-stage Disease (PREVEND)
suggested a sex differences in the association between
copeptin and diabetes, that was detected in women but not
in men. A sex-related association between copeptin and
diabetes was also found by The British Regional Heart
Study that 13-years followed up about 3500 patients with
no diabetes. Conversely the PREVEND study, The British
Regional Heart Study showed an association between the
risk of incident diabetes and copeptin only in old men and
this risk persisted after adjustment for several diabetes risk
factors including metabolic risk factors and C-reactive
protein but not in women [20]. This discrepancy could be
explained by the fact that The British Regional Heart Study
was performed in elderly subjects in which the
hypothalamic-pituitary-adrenal axis reactivity could be
more responsive to the stimulation of AVP than younger
adults [21]. This may explain the positive association
between copeptin and diabetes in elderly men (The British
Regional Heart Study) but not in young men (the PRE-
VEND study). The lack of a sex-related analysis of the data
might also be a bias that could explain the different results
coming from The Malmo Diet and Cancer Study and The
FINRISK97 study. Indeed, The Malmo Diet and Cancer
Study from a Swedish population-based cohort included
4472 participants with 174 incident cases who were older
(mean age of 58 years) and included around 60% women
[22]. In the The Malmo Diet and Cancer Study study,
including a higher number of women who had comparable
copeptin levels to those of PREVEND study, a potential
sex-related effect on the association of copeptin with dia-
betes risk was not investigated. The FINRISK97 study from
a cohort of 7827 participants with 417 incident cases
included similar numbers of women and men. In the
FINRISK97 study, a higher but non-signiﬁcant risk of type
2 diabetes per one standard deviation increase in copeptin
has been detected in the total and sex-stratiﬁed population.
In this latter study, the range of copeptin levels was smaller
than in The Malmo Diet and Cancer Study and PREVEND
study, for both women and men. Theoretically, this smaller
range may also lead to overlap of copeptin levels between
individuals with and without type 2 diabetes in the latter
study, which could represent a limit for the predictive value
of copeptin. The sex-related difference of the association
between copeptin and type 2 diabetes lead to hypothesize
that there could be differences between men and women in
responsiveness to the vasopressin system due to a higher
sensitivity of both AVP V1a and V1b receptors to of AVP
in women than in men [23, 24]. The gender effect on AVP
secretion was suggested in 1979 by Skowsky et al. [25] that
reported an increase in plasma AVP 2 weeks after male rats
were castrated; this phenomenon was reversed by testos-
terone administration. The estrogen treatment resulted,
instead, in an increase of AVP [25]. Thus, these ﬁndings
suggested that androgens inhibit and estrogen stimulates
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AVP secretion. Opposite results were found by Crofton et al
that reported a decrease in AVP following castration of
male rats and an increase in AVP with testosterone treat-
ment [26]. The same authors observed no changes in AVP
levels in female rats treated with estrogen treatment alone
while they detected a decrease when the animals were
treated with a combined administration of estrogen and
progesterone [26]. A human study reported a midcycle
increases in AVP in women even if this was not conﬁrmed
in other studies [26–30]. In obese women affected by
(Polycystic Ovary Syndrome) PCOS an increase in copeptin
levels has been reported compared to lean women. More-
over, copeptin levels were related to (Body Mass Index)
BMI, (Waist hip ratio) WHR, hirsutism score, total testos-
terone, and HOMA-IR, thus suggesting that copeptin could
be a predictive factor of the severity of the syndrome and of
the cardiovascular risk in this pathological setting [31].
Although the results of the above reported studies were
controversial, they suggested the effects of gonadal steroids
on AVP secretion and action, in fact gonadal steroids have
been reported not only to act on afferents to the AVP neuron
but also on the AVP neuron itself and on AVP target tissues
[26–29]. Altered vasopressin metabolism, interaction
between insulin and vasopressin, both of which act in the
renal collecting duct, and the reabsorption of more hypo-
tonic ﬂuid due to slower stomach emptying have been also
proposed as possible underlying mechanism [32, 33].
Moreover, the association between hyperglycemia and high
copeptin levels has been hypothesized to have a genetic
background. In the Data from Epidemiological Study on the
Insulin Resistance Syndrome study the CC genotype of
rs6084264, the TT genotype of rs2282018, the C-allele of
rs2770381, and the CC genotype of rs1410713 have been
identiﬁed to be associated with incidence of hyperglycemia
and high copeptin levels [34]. Although several evidence
supported a role for copeptin as a marker of diabetes risk,
the current ﬁndings were too scarce to prove that there is an
actual causal association between elevated copeptin con-
centration and diabetes risk. Copeptin has been also iden-
tiﬁed as a predictive marker of diabetic complications
(35–47). In addition, type 2 diabetes is often complicated by
hepatic steatosis and low AVP levels have been demon-
strated to have a protective effect to hepatic steatosis and
this seems to be due to the reduced expression of hepatic
lipogenic genes. However, this association has been detec-
ted in animal studies but needs to be conﬁrmed in human
studies [35]. Wang et al. [36] investigated the role of
copeptin as predictor marker of functional outcome in
patients with ischemic stroke and type 2 diabetes. High
levels of copeptin have been associated to a worsen func-
tional outcome and a higher risk of mortality at 3 months
follow-up after the event. A prognostic importance of
copeptin has been identiﬁed in the context of myocardial
infarction in type 2 diabetes. Copeptin predicted major
cardiovascular events, cardiovascular mortality and total
death in people with diabetes followed over a decade for
major cardiovascular events in unadjusted analysis [37].
Similar results were reached in the DIGAMI 2 trial that
followed up about 400 people with diabetes for 2.5 years in
which copeptin has been reported to predict cardiovascular
events after myocardial infarction in diabetic subjects [38].
Further, in diabetic individuals, copeptin predicted the
combined end point coronary artery disease (CAD), heart
failure (HF), and death after adjustment for conventional
risk factors [39]. However copeptin is not only a marker of
overt cardiovascular disease but also a marker of early
cardiovascular derangements. Indeed copeptin has been
found to be higher in people with diabetes without known
cardiovascular diseases but with peripheral arterial disease
[40]. An association of V1-vascular vasopressin receptor
gene microsatellite polymorphisms in human essential
hypertension has been investigated in humans. Analysis of
these polymorphisms were performed in 79 hypertensive
and 86 normotensive subjects. No linkage was found in
hypertensive patients, thus suggesting that molecular var-
iants of the V(1)R gene are not involved in unselected forms
of essential hypertension [41].
Besides macrovascular complications, the role of pre-
dictive marker of copeptin has been also highlighted in the
context of microvascular complications. In a cross-sectional
analysis, copeptin was strongly related to diabetic kidney
disease and coronary atherosclerosis in adults with type 1
diabetes [42]. In addition, in patients with diabetes, a higher
baseline copeptin concentration is signiﬁcantly associated
with kidney function decline during follow-up [43]. Pik-
kemaat et al. [44] investigated the association of copeptin
with development of chronic kidney disease in people with
diabetes. People with newly diagnosed type 2 diabetes in
1996–1998 were followed up after about 10 years. Elevated
copeptin levels at the baseline predicted the risk of devel-
oping chronic kidney disease 10 years later. Similar results
were previously found in the the DIABHYCAR trial in
which diabetic subjects with albuminuria were followed up
for 6 years. Plasma copeptin concentration was tightly
associated with the risk of severe renal outcomes (doubling
of plasma creatinine concentration and/or end-stage renal
disease) in patients with type 2 diabetes and albuminuria.
This association was independent of relevant covariates
such as age, duration of diabetes, blood pressure, and
baseline levels of HbA1c, urinary albumin excretion, and
(Estimated glomerular ﬁltration rate) eGFR [45]. As evi-
denced that AVP plays a direct role in the pathophysiology
of kidney dysfunction, DDAVP (a selective vasopressin V2
receptor agonist) was infused in healthy subjects and in
normal rats [46] resulting in an increased urinary albumin
excretion (UAE). Furthermore, treatment with a selective
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vasopressin V2 receptor antagonist prevented the increase
in albuminuria in rats with streptozotocin-induced diabetes
[47].
Basic evidence
A low water intake ( < 1.2 litres/day of total ﬂuid intake)
results in an increased plasma AVP in order to preserve
ﬂuid homeostasis [48]. AVP may bind V1b receptor at
pituitary level stimulating ACTH secretion as well as
enhancing the effect of CRH [8, 49–51]. This may results in
a Cushing’s Syndrome like increase in the secretion of
cortisol. Interestingly, the AVP stimulated secretion of
cortisol lacks a negative feed-back loop, which may initiate
a vicious circle of cortisol release [51]. In fact, low drinkers
have been reported to have signiﬁcantly higher plasma
cortisol levels [48]. The pleiotropic effects of glucocorti-
coids include the upregulation of the serum and gluco-
corticoid inducible kinase 1 (SGK1) that stimulates the
intestinal Na+ coupled glucose transporter (SGLT)-1 [52].
The increased activity of this carrier plays an important role
in the development of obesity; an increased post-prandial
glucose absorption due to the upregulation of SGLT-1
represents a powerful stimulus to insulin secretion and
subsequent fat deposition [53, 54]. SGK1 has also a direct
action on adipocyte differentiation and adipogenesis [55]. In
addition to these pituitary effects, AVP regulates insulin and
glucagon secretion through V1b receptor and promotes
hepatic glycogenolysis and gluconeogenesis through V1a
receptor [4–6] (Fig. 1). Moreover, cortisol potentiates
glucagon-stimulated gluconeogenesis in an additive man-
ner, thus contributing to increase glucose output [56]. Fur-
ther, hyperosmolality, which is a consequence of the low
water intake and at the same time a stimulus for AVP
secretion, could per sè contribute to the onset of insulin
resistance [57]. Although AVP has been reported to sti-
mulate insulin secretion [58, 59], this beneﬁcial effect on
glucose metabolism may not be able to counteract the
several negative effects related to the increased cortisol
secretion, glycogenolysis, and gluconeogenesis, thus
resulting in a ﬁnal hyperglycemic effect of AVP. Despite it
has been demonstrated these direct effect of AVP on target
organs that are involved in glucose homeostasis, the con-
tribution of AVP to glucose metabolism seems to be rather
complex. Mice with selective deletion of V1a R developed
elevated glucose levels, predisposition for obesity and dia-
betes, low triglycerides levels, and enhanced lipid
Low Water Intake
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Fig. 1 Mechanism of action of copeptin. Low water intake stimulates
the secretion of copeptin that in turn potentiates CRH action resulting
in an increased ACTH and cortisol secretion. Copeptin acts on liver
stimulating glycogenolysis and gluconeogenesis. Further, pancreas is
another target of copeptin, which contributes to the regulation of
insulin and glucagon secretion
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metabolism [7, 60], whereas mice lacking V1b R showed a
phenotype characterized by low glucose levels and
increased insulin sensitivity [61]. In humans, the rs1042615
polymorphism of the V1aR gene was associated with obe-
sity and metabolic complications such type 2 diabetes and
low triglycerides resembling the phenotype of the mouse
with V1aR deletion [62, 63]. In addition, AVP promotes
water reabsorption through stimulation of V2 receptors,
thus increased levels of AVP limit glucose-induced water
loss in patients with diabetes [64]. Increased levels of AVP
may, however, have long-term deleterious renal and cardi-
ovascular effects [36–39, 43–46]. In animal studies it has
been demonstrated that AVP causes hyperﬁltration, albu-
minuria, and renal hypertrophy in diabetes [45, 65]. In fact,
drinking water or treatment with V2 receptor antagonist in
rats with renal failure has been reported to have a renal
protective effect both in diabetic and non-diabetic condition
[46, 66, 67]. The involvement of AVP in diabetic cardio-
vascular complications could be explained by the fact that
high concentrations of plasma AVP has been demonstrated
to bind V1a receptors preferentially [68], which results in
coronary vasoconstriction [69], increasing afterload, ven-
tricular stress, and cardiac hypertrophy [70, 71].
Conclusions
In summary, a large number of studies identiﬁed high levels
of copeptin as a novel risk factor for the development of
diabetes. The most likely pathophysiological mechanism is
insufﬁcient ﬂuid intake that leads to increased AVP secre-
tion, which in turn stimulates the secretion of ACTH and
cortisol resembling a Cushing syndrome like-phenotype.
Thus, encouraging water intake, which is linked to the
decrease of copeptin appears a broadly, applicable, safe,
cost-effective, and easy-to implement primary preventive
intervention, especially in patients at high risk of develop-
ing type 2 diabetes. Strategy intervention to implement
water intake should be evaluated in future large randomized
controlled clinical trials in order to investigate if the
assumption of adequate intake of water could represent a
preventive factor to metabolic diseases. Further, there is
need to identify the optimal water intake that should be
recommended as prevention/treatment of the different
metabolic diseases, adjusted for gender and age.
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